Advertisement

Topics

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Company Profile

09:04 EST 13th December 2018 | BioPortfolio

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996, IAVI works with partners in 25 countries to research, design and develop AIDS vaccine candidates. In addition, IAVI conducts policy analyses and serves as an advocate for the AIDS vaccine field. IAVI supports a comprehensive approach to addressing HIV and AIDS that balances the expansion and strengthening of existing HIV-prevention and treatment programs with targeted investments in the design and development of new tools to prevent HIV. IAVI is dedicated to ensuring that a future AIDS vaccine will be available and accessible to all who need it. IAVI’s Innovation Fund supports the application of novel and unconventional technologies to AIDS vaccine design and development, and is partially supported by the Bill & Melinda Gates Foundation. IAVI relies on the generous donations from governments, private individuals, corporations and foundations to carry out its mission. For more information, see www.iavi.org.


News Articles [2640 Associated News Articles listed on BioPortfolio]

Researchers launch Phase 1 trial of HIV vaccine

Researchers working with the non-profit organisation the International AIDS Vaccine Initiative (IAVI) have announced the launch of a Phase I clinical trial, aiming to test a novel vaccine candidate fo...

Batavia partners with IAVI to advance development of vaccine against Lassa fever

The International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine

[Comment] A new step towards an HIV/AIDS vaccine

A preventive vaccine is an essential part of the strategy to eradicate the HIV pandemic.1 Although the search for an AIDS vaccine has led to many scientific advances, a vaccine remains out of reach. M...

AIDS vaccine offers hope in early trial – The Hindu

The HinduAIDS vaccine offers hope in early trialThe HinduThe near 40-year quest for an AIDS vaccine received a hopeful boost on Saturday when scientists announced that a trial drug triggered an immune...

Why Don't We Have an AIDS Vaccine?

I mentioned to a friend, a gay man nearing 60, that World AIDS Day, which has been observed on Dec. 1 since 1988, was almost upon us. He had no idea that World AIDS Day still exists. This lack of kn...

Seqirus to join universal flu vaccine initiative

Manufacturer of egg-based influenza vaccines in the UK, Seqirus, has revealed it is joining the Human Vaccines Project’s Universal Influenza Vaccine Initiative (UIVI) — a collaborative effort to a...

IAVI starts Phase l trial of eOD-GT8 60mer for HIV

International AIDS Vaccine Initiative (IAVI) has commenced the Phase I IAVI G001 clinical trial to evaluate safety and immunogenicity of...Read More... The post IAVI starts Phase l trial of eOD-GT8 60...

GlycoMimetics doses first patient in Phase III trial of uproleselan

GlycoMimetics has dosed the first patient in a Phase III clinical trial of uproleselan (GMI-1271) to treat relapsed / refractory...Read More... The post GlycoMimetics doses first patient in Phase III ...

PubMed Articles [2521 Associated PubMed Articles listed on BioPortfolio]

Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India.

A Phase I HIV-1 vaccine trial sponsored by the International AIDS Vaccine Initiative (IAVI) was conducted in India in 2009 to test a subtype C prophylactic vaccine in a prime-boost regimen comprising ...

Monkey Models and HIV Vaccine Research.

Since the discovery of acquired immunodeficiency syndrome (AIDS) in 1981, it has been extremely difficult to develop an effective vaccine or a therapeutic cure despite over 36 years of global efforts...

Prospects for a vaccine to prevent HIV-related tuberculosis.

To outline the need for a new tuberculosis (TB) vaccine; challenges for induction of vaccine-mediated protection in HIV-infected persons; and recent advances in clinical development.

Multimonth Prescription of Antiretroviral Therapy Among Children and Adolescents: Experiences From the Baylor International Pediatric AIDS Initiative in 6 African Countries: Erratum.

The Evolution of the Secretary's Minority AIDS Initiative Fund: The US Department of Health and Human Services Responds to the National HIV/AIDS Strategy.

Clinical Trials [5886 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndr...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)

Major Research Aim: To study novel molecular diagnostics and the pharmacokinetic variability among a spectrum of TB disease states, including severe forms of TB like disseminated TB, TB me...

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines ...

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk o...

Companies [2985 Associated Companies listed on BioPortfolio]

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Found...

IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV ...

International AIDS Vaccine Initiative

The International AIDS Vaccine Initiative (IAVI)

Selexis SA and International AIDS Vaccine Initiative (IAVI)

More Information about "GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC" on BioPortfolio

We have published hundreds of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC news stories on BioPortfolio along with dozens of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Clinical Trials and PubMed Articles about GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Companies in our database. You can also find out about relevant GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record